Renowned cancer researcher Dan Von Hoff, M.D. joins InNexus Scientific Board

July 16, 2009

By Flinn Foundation

[Source: InNexus] – InNexus Biotechnology Inc. a drug development company commercializing the next generation of antibodies based on its groundbreakingDynamic Cross Linking technology, announced today the addition of noted clinical oncologist and cancer research pioneer Daniel Von Hoff, MD. to the InNexus Scientific Advisory Board.

Dr. Von Hoff is Physician in Chief of The Translational Genomics Institute (TGen), Executive Vice President and Director of TGen’s Translational Drug Development Division and Head of TGen’s Pancreatic Cancer Research Program.  His other accomplishments include:


  • Chief Scientific Officer for U.S. Oncology, the nation’s premier cancer treatment and research network

  • Past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, a member and past board member of the American Society of Clinical Oncology, and was appointed by President Bush to the National Cancer Advisory Board in June 2004

  • Graduated cum laude from Carroll University, Dr. Von Hoff received his M.D. from Columbia University College of Physicians and Surgeons

  • He is the author of more than 525 scientific papers, 130 book chapters, and 950 abstracts

“We have known Dr. Von Hoff for quite some time, and have been considering several ways to bring the benefit of Dan’s wisdom and experience to the InNexus team,” said InNexus Chairman and CEO Jeff Morhet.  “We are delighted to welcome Dan to the Scientific Advisory Board, and are thrilled at the prospect of leveraging a shared passion for the development and pursuit of novel anticancer agents.”  To meet and see the full InNexus Scientific Advisory Board, go to:

Dr. Von Hoff stated, “I am pleased to become a member of the InNexus Scientific Advisory Board.  Jeff and his team have been at the forefront of the development of newer and potentially safer, more effective antibodies for the treatment of cancer and numerous other diseases.  I look forward to contributing and building on those efforts and exciting work.” 

News of the addition of Dr. Von Hoff follows InNexus’ recently announced successful meeting with the FDA, where the agency expressed clear support for the company’s product development plans following a comprehensive review of the proposed clinical pathway for its lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin’s Lymphoma and/or Chronic Lymphocytic Leukemia.

The agency also provided a Manufacturing Exception Approval allowing InNexus to manufacture all clinical material needed for DXL625’s Phase l human trial, in its facilities located on the campus of Mayo Clinic in Scottsdale, Arizona